ProQR Therapeutics (PRQR) Depreciation & Amortization (CF) (2013 - 2022)

ProQR Therapeutics' Depreciation & Amortization (CF) history runs 10 years deep, the most recent figure standing at $763145.0 for Q4 2022.

• In Q4 2022, Depreciation & Amortization (CF) rose 20.85% year-over-year to $763145.0; the TTM figure through Sep 2023 stood at $763145.0 (down 69.7% YoY), while the FY2025 annual figure was $3.1 million, up 6.64% from the prior year.
• Depreciation & Amortization (CF) came in at $763145.0 for Q4 2022 at ProQR Therapeutics, up from $617063.9 in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $777373.0 in Q4 2020 to a low of $294.85 in Q1 2018.
• A 5-year average of $520116.8 and a median of $604623.8 in 2019 frame the typical range for Depreciation & Amortization (CF).
• Across the five-year window, Depreciation & Amortization (CF) jumped 200743.79% in 2019 and plunged 99.9% in 2020, its largest moves.
• ProQR Therapeutics' Depreciation & Amortization (CF) stood at $304.75 in 2018, then surged by 184773.03% to $563405.8 in 2019, then soared by 37.98% to $777373.0 in 2020, then dropped by 18.77% to $631472.0 in 2021, then grew by 20.85% to $763145.0 in 2022.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $763145.0, $617063.9, and $630630.5 for Q4 2022, Q3 2022, and Q2 2022 respectively.

Peer Comparison